Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54

Benzinga Newsdesk www.benzinga.com Negative 63.3%

Neg 63.3% Neu 0% Pos 0%

Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $68 to $54.